TD Cowen Upgrades Pacira BioSciences to Outperform, Announces $50 Price Target
Portfolio Pulse from richadhand@benzinga.com
TD Cowen analyst Boris Peaker has upgraded Pacira BioSciences (NASDAQ:PCRX) from Market Perform to Outperform and announced a $50 price target.
August 04, 2023 | 12:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pacira BioSciences has been upgraded to Outperform by TD Cowen with a new price target of $50.
The upgrade from TD Cowen is a positive signal for Pacira BioSciences. The new price target of $50 suggests that the analyst sees significant upside potential for the stock. This could lead to increased investor interest and potentially a higher stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100